FDA 483 OBSERVATION · #61 OF 1,923 MOST-CITED
Procedures for sterile drug products
FDA cited this observation 416 times across 331 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Written procedures to prevent microbiological contamination of drug products purporting to be sterile were absent or inadequate — including validation of the sterilization process and the aseptic controls that keep a sterile product sterile.
Why FDA writes it — A sterile product that is not actually sterile can kill. Because sterility cannot be fully tested into a batch, it must be built in through validated sterilization and rigorously controlled aseptic processing — so missing or weak procedures here are among the most serious findings FDA makes.
- Establish and follow written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including validation of any sterilization process.
- Validate the sterilization process and demonstrate it reliably achieves sterility, with defined parameters and routine monitoring.
- Control the aseptic process — environment, gowning, interventions, media fills — under a contamination-control approach.
- Investigate every sterility failure and environmental excursion thoroughly, and assess impact on other batches.
- Reliance on end-product sterility testing instead of a validated, designed-in sterility assurance.
- Aseptic process controls that are documented but not reflected in actual behaviour on the line (interventions, gowning breaches).
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.5× the rate of the average FDA-cited firm (42.6% vs 7.8%), across 331 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →